US 12,031,135 B2
p63 inactivation for the treatment of heart failure
Vivekkumar B. Patel, Houston, TX (US); Hongran Wang, Houston, TX (US); Vivek P. Singh, Houston, TX (US); Erin Lynn Reineke, Houston, TX (US); Megumi Mathison, Houston, TX (US); Austin J. Cooney, Houston, TX (US); and Todd Rosengart, Houston, TX (US)
Assigned to Baylor College of Medicine, Houston, TX (US)
Filed by Baylor College of Medicine, Houston, TX (US)
Filed on Jul. 19, 2022, as Appl. No. 17/813,493.
Application 17/813,493 is a continuation of application No. 15/552,253, granted, now 11,421,229, previously published as PCT/US2016/018735, filed on Feb. 19, 2016.
Claims priority of provisional application 62/118,573, filed on Feb. 20, 2015.
Prior Publication US 2022/0348921 A1, Nov. 3, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 31/47 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01); C07K 14/82 (2006.01); C12N 5/077 (2010.01); C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [A61K 9/0019 (2013.01); A61K 31/47 (2013.01); A61K 31/713 (2013.01); A61K 38/1709 (2013.01); A61K 48/0058 (2013.01); C07K 14/4702 (2013.01); C07K 14/4746 (2013.01); C07K 14/82 (2013.01); C12N 5/0657 (2013.01); C12N 15/1135 (2013.01); C12N 15/86 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); C12N 2501/60 (2013.01); C12N 2710/10043 (2013.01); C12N 2740/15043 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A composition for reprogramming differentiated cardiac cells to cardiomyocyte-like cells, the composition comprising one or more nucleic acid vectors, said vectors comprising one or more agents that inactivates p63 and comprising one or more cardiac cell reprogramming factors, wherein the cardiac cell reprogramming factors comprise Hand2 nucleic acids and myocardin nucleic acids.